

WHAT IS CLAIMED IS:

1. A process for stimulating the immune system of a subject to produce and release antimalignin antibody, said process comprising administering to the subject an effective amount of a first dosage of a composition comprising malignin, recognin M, Recognin L or a peptide having the immunological specificity thereof.

2. The process of claim 1 wherein the composition is administered as an approximately 1 mg dosage form.

3. The method of claim 1 further comprising administering a second dose of the composition ten days after administration of the first dosage.

4. The method of claim 3 further comprising administering a third dose of the composition ten days after administration of the second dosage.

5. A composition for stimulating the immune system of a subject to produce and release antimalignin antibody, said composition comprising malignin, recognin M, recognin L or a peptide having the immunological specificity thereof.

6. An antimalignin antibody.

7. A device for removing cancer cells from the body of a subject, said device comprising cells having immunological specificity for malignin, recognin L or recognin M, wherein said device binds, absorbs or engulfs cancer cells which come into contact therewith.

8. The device of claim 7 wherein said device comprises a filter through which the cancer cells are passed.

9. The device of claim 7 wherein the device comprises a surface over which the cancer cells are passed.

10. The device of claim 7 wherein the device comprises a resin over which the cancer cells are passed.

11. The device of claim 7 wherein the cells are selected from the group consisting of T cells, B cells and phagocytes.

12. A process for ascertaining the presence of cells transformed to the malignant state in a subject

(1) obtaining a fluid or tissue specimen from the subject;

(2) quantifying the amounts of antimalignin antibody and/or immune cells having specificity for malignin, recognin L and/or recognin M in the fluid or tissue specimen;

(3) correlating the amounts to the presence of cells transformed to the malignant state.

13. An antimalignin antibody having a cytotoxic agent attached thereto.